Segment information

3 Months Ended

Mar. 31, 2016

Segment information [Abstract]

Segment information

9. Segment information

On August 6, 2015, Emergent BioSolutions Inc. (the "Company" or "Emergent"), announced its plan to separate into two independent publicly-traded companies, one a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives and the other a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In anticipation of the planned spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment.  Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Aptevo. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments offer different products, product candidates, manufacturing processes and services, development processes, sales and marketing processes, and are managed separately.

The Biodefense division consists of three business units: vaccines and therapeutics, medical devices and contract manufacturing. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Aptevo division consists of one business unit: the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Aptevo.

	Reportable Segments
(in thousands)	Biodefense			Aptevo			Total
Three Months Ended March 31, 2016
External revenue	$	102,969		$	8,033		$	111,002
Intersegment revenue (expense)		574			(574	)		-
Income (loss) from operations		23,016			(14,455	)		8,561
Total assets		925,125			110,772			1,035,897
Three Months Ended March 31, 2015
External revenue	$	52,147		$	11,486		$	63,633
Intersegment revenue (expense)		104			(104	)		-
Income (loss) from operations		(18,496	)		(9,814	)		(28,310	)
Total assets		799,017			118,828			917,845